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Abstract: Eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3) are important for leuko-
cyte function. This study investigated whether consuming transgenic Camelina sativa (tCSO) seed oil
containing both 20:5n-3 and 22:6n-3 is as effective as fish oil (FO) for increasing the 20:5n-3 and 22:6n-3
content of leukocytes and altering mitogen-induced changes to the T cell transcriptome. Healthy
adults (n = 31) consumed 450 mg/day of 20:5n-3 plus 22:6n-3 from either FO or tCSO for 8 weeks.
Blood was collected before and after the intervention. 20:5n-3 and 22:6n-3 incorporation from tCSO
into immune cell total lipids was comparable to FO. The relative expression of the transcriptomes of
mitogen-stimulated versus unstimulated T lymphocytes in a subgroup of 16 women/test oil showed
4390 transcripts were differentially expressed at Baseline (59% up-regulated), 4769 (57% up-regulated)
after FO and 3443 (38% up-regulated) after tCSO supplementation. The 20 most altered transcripts
after supplementation differed between test oils. The most altered pathways were associated with
cell proliferation and immune function. In conclusion, 20:5n-3 and 22:6n-3 incorporation into im-
mune cells from tCSO was comparable to FO and can modify mitogen-induced changes in the T cell
transcriptome, contingent on the lipid matrix of the oil.
Keywords: omega-3; RNAseq; T lymphocyte; transgenic plant; fish oil; eicosapentaenoic acid;
docosahexaenoic acid
1. Introduction
The omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (20:5n-3)
and docosahexaenoic acid (22:6n-3) are important components of cell membranes that are
required for normal tissue function and development. The proportions of these PUFAs
in the lipid bilayer can influence cell function by conferring fluidity on the lipid bilayer
and thus influence the activities of integral membrane proteins. For example, reducing the
amount of 22:6n-3 in retinal cell membranes can impair rhodopsin activation [1] and visual
function [2]. 20:5n-3 and 22:6n-3 can also modulate gene transcription via the activities
of ligand-activated transcription factors [3], namely peroxisome proliferator-activated
receptors, as well as by inducing changes in the epigenome [4].
Oily fish are the primary dietary source of 20:5n-3 and 22:6n-3, although meat and
dairy foods may also contribute to the total intake of these PUFAs [5]. Dietary supple-
mentation with fish oil (FO) can modify the immune response [6]. 20:5n-3 and 22:6n-3 are
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incorporated into peripheral blood mononuclear cells (PBMCs) in a dose-dependent man-
ner [7] and can reach an equilibrium after 4 weeks of dietary supplementation, although
immunomodulatory effects have been observed within 1 week of starting the interven-
tion [8]. Dietary supplementation with FO can induce a modest reduction in the symptoms
of inflammatory diseases such as rheumatoid arthritis [9]. Such anti-inflammatory effects
involve the partial displacement of 20:4n-6 by 20:5n-3 from cell membranes and increased
synthesis of less biologically active eicosanoids derived from 20:5n-3, namely 3-series
prostaglandins (PG) and 5-series leukotrienes [10–12], as well as reduction in the production
of more pro-inflammatory PGE2 and 4-series leukotrienes from mononuclear cells [13–15]
and decreased secretion of leukotriene B4 by neutrophils and monocytes [16–19]. In addi-
tion, the amelioration of an inflammatory response by 20:5n-3 and 22:6n-3 may involve
increased synthesis of anti-inflammatory and inflammation-resolving mediators, namely
resolvins, protectins and maresins [20].
General consumption of 20:5n-3 and 22:6n-3 in UK adults is 50% of the 450 mg (20:5n-
3 plus 22:6n-3) per day dose recommended by the UK Government [5,21,22]. Failure to
achieve recommended intakes reflects food choices that exclude oily fish on the grounds
of cost, unpalatability or personal preference, and concerns about contamination with
environmental pollutants and the sustainability of marine sources [5,21]. 20:5n-3 and 22:6n-
3 intakes by individuals who exclude all animal-derived foods may be close to zero [23].
Fish oil (FO) is a supplemental source of 20:5n-3 and 22:6n-3. A transgenic strain of Camelina
sativa has been developed that produces a seed oil (tCSO) containing similar amounts of
both 20:5n-5 and 22:6n-3 as found in FO [24], and it is as effective as FO as a source of
these fatty acids in the human diet [25,26]. However, it is not known whether this seed oil
can induce changes in leukocytes that are comparable to those associated with increased
consumption of FO or oily fish.
To address this, we compared the effect of dietary supplementation with tCSO or FO
on the incorporation of 20:5n-3 and 22:6n-3 into PBMCs and on mitogen-induced changes
in the T cell transcriptome.
2. Methods
2.1. Preparation of Seed Oil from Transgenic C. sativa
tCSO was prepared as described [25]. Briefly, homozygous T3 generation transgenic
C. sativa plants producing a seed oil containing 20:5n-3 and 22:6n-3 [24] were grown
in a biological containment glasshouse with 16 h light/8 h dark cycles (illumination of
400 µmol/m2 per second) and 23 ◦C (day) to 18 ◦C (night) cycles at 50–60% relative
humidity [25]. Seeds were harvested and threshed, and the oil was then extracted and
processed for human consumption by POS Bio-Sciences [25].
2.2. Dietary Supplementation
The details of the dietary supplementation study have been reported previously [25].
Briefly, the 31 healthy men and women who enrolled in the study were between 18 and
75 years of age, with a BMI between 18.5 and 30.0 kg/m2, were normotensive and had
non-fasting total cholesterol and glucose concentrations within the normal ranges (Table 1).
Volunteers who did not meet these criteria or habitually consumed any dietary oil sup-
plements or more than one oily fish meal per week, who were unable to provide written
informed consent, who were pregnant or intending to become pregnant, who were receiv-
ing treatment for a clinician-diagnosed chronic illness or who had any food allergy were
excluded. Because the acute incorporation of 20:5n-3 and 22:6n-3 into blood lipids did not
differ between sexes [25], the participants were studied as a single group of mixed ages
and sexes (Table 1). In order to match the groups assigned to each test oil, a subgroup of 16
women, from which the highest T cell RNA yield was produced, were selected for RNAseq
analysis (Table 1). Samples collected from men were not included in these analyses because
of insufficient numbers of male participants to match the groups.
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Table 1. Characteristics of participants. Values are mean ± SEM. There were no significant differences by Student’s unpaired
t-test between males and females, and all females and the RNAseq subgroup at Baseline. * All participants in the RNAseq
subgroup were female. ‡ Comparison between the FO and tCSO RNAseq subgroups by Student’s unpaired t-test.
Whole Group Males Females RNAseq Subgroup *
All (Baseline) FO Group tCSO Group ‡ t Test
n 31 13 18 16 8 8 p
Age (years) 44.6 ± 3.4 46.6 ± 5.3 43.1 ± 4.9 44.4 ± 5.5 40.1 ± 7.9 46.1 ± 7.6 0.595
BMI (kg/m2) 24.5 ± 0.5 25.2 ± 0.8 23.9 ± 0.6 26.6 ± 5.5 23.2 ± 1.3 24.3 ± 0.7 0.468
Systolic bp
(mm Hg) 118 ± 2 123 ± 2 114 ± 3.5 106 ± 8 117 ± 5.3 111.6 ± 5.8 0.522
Diastolic bp
(mm Hg) 69 ± 2 73 ± 2 66 ± 2 65 ± 2 66.9 ± 2.8 65.3 ± 2.9 0.713
Glucose
(mmol/L) 5.1 ± 0.1 4.9 ± 0.1 5.3 ± 0.2 5.4 ± 0.2 5.1 ± 0.2 5.6 ± 0.4 0.258
Cholesterol
(mmol/L) 4.9 ± 0.2 4.8 ± 0.2 5.0 ± 0.3 5.2 ± 0.3 5.2 ± 0.4 4.9 ± 0.5 0.665
The trial had a single blinded crossover design, because it was not possible to conceal
the odour of the FO from the participants [25]. Those who took part were randomised using
a random number generator (www.random.org, accessed on January 2019) to consume
either the tCSO (2.4 mL/day) or a commercial blended FO (Simply Timeless®, Omega-3
Fish Oil plus Cod Liver Oil; Seven Seas, Weybridge, Surrey, UK; 1.6 mL/day) in random
order for 56 days followed by 42 days of washout, during which participants consumed
their habitual diet and then consumed the other test oil for 56 days. However, because
of the risk of carry over between the phases of supplementation, only data for samples
collected during the first period of supplementation are reported here. The test oils were
matched to provide approximately 450 mg of 20:5n-3 plus 22:6n-3 per day based on the
amount recommended by the UK Government [22]. Daily and cumulative intakes of
fatty acids from the test oils are shown in Table 2. Participants dispensed the appropriate
volume of test oil using an oral dosing syringe and consumed this with food. Compliance
was assessed by the change in weight of the bottles containing the test oils compared to
the expected weight change. After fasting for 12 h, venous blood samples (40 mL) were
collected into tubes containing lithium heparin anticoagulant at the start and end of each
period of supplementation and separated into plasma and cell fractions [25]. PBMCs
were isolated by using Histopaque (Sigma-Aldrich, Poole, Dorset, UK) density gradient
centrifugation [27]. Plasma and PBMCs were stored at −80 ◦C before the analysis of fatty
acid composition. Any participants who exhibited symptoms of infection were asked to
postpone blood sampling until they were asymptomatic and then for a further 14 days.
Table 2. Fatty acid provision from test oil supplements. Values are the amounts of each fatty acid provided by tCSO or FO to
each participant daily and the cumulative amount provided over the 56 days intervention period. MUFAs, monounsaturated
fatty acids, PUFAs, polyunsaturated fatty acids, SFAs, saturated fatty acids.
Fatty Acid Daily Provision (mg/day) Cumulative Provision (g over 56 days)
FO tCSO FO tCSO
14:0 100 3 5.6 0.2
16:0 232 156 13.0 8.7
18:0 45 130 2.5 7.3
20:0 3 68 0.1 3.8
24:0 2 24 0.1 1.3
Total SFAs 381 380 21.4 21.3
16:1n-7 139 5 7.8 0.3
18:1n-9 224 139 12.6 7.8
18:1n-7 63 37 3.5 2.1
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Table 2. Cont.
Fatty Acid Daily Provision (mg/day) Cumulative Provision (g over 56 days)
FO tCSO FO tCSO
20:1n-9 102 144 5.7 8.0
Total MUFAs 527 325 29.5 18.2
18:2n-6 24 468 1.4 26.2
18:3n-6 3 73 0.2 4.1
20:2n-6 4 20 0.2 1.1
20:3n-6 3 21 0.2 1.2
20:4n-6 15 67 0.9 3.8
Total n-6 PUFAs 50 650 2.8 36.4
18:3n-3 16 321 0.9 18.0
20:4n-3 96 66 5.4 3.7
20:5n-3 247 254 13.8 14.2
22:5n-3 29 155 1.6 8.7
22:6n-3 199 202 11.1 11.3
20:5n-3 + 22:6n-3 445 456 24.9 25.5
Total n-3 PUFAs 587 998 33 56
Total fatty acids 1545 2352 86.5 131.7
2.3. T Cell Isolation and Culture
For RNAseq analysis, CD3+ T cells were purified from PMBCs by negative selection
using the EasySep™ Human T Cell Isolation Kit (StemCell Technologies, Cambridge,
Cambridgeshire, UK) according to the manufacturer’s instructions. The proportion of
CD3+ cells in the T cell fraction was determined by flow cytometry and found to be
between 80.4% and 87.7%.
Cells were cultured for 48 h in RPMI-1640 medium (Sigma-Aldrich, Poole, Dorset, UK)
containing L-glutamine (2 mM), penicillin (100 units/mL) and streptomycin/(100 µg/mL),
as well as 10% (v/v) autologous plasma with or without 10 µg/mL concanavalin A (Sigma-
Aldrich, Poole, Dorset, UK). At 48 h, cells were collected by centrifugation, washed with
PBS and the pellets were either frozen directly or resuspended in RNAlater (ThermoFisher
Scientific, Oxford, Oxfordshire, UK) and then stored at −80 ◦C.
2.4. Analysis of Fatty Acid Composition by Gas Chromatography
Fatty acid analysis of total PBMC lipids was carried out as described [26]. Frozen
PBMCs were thawed, and total cell lipids were then extracted with chloroform:methanol
(2:1, v/v) containing butylated hydroxytoluene (50 mg/mL) [28]. Fatty acid methyl esters
(FAMEs) were synthesised by reaction with methanol containing (2% v/v) concentrated
sulphuric acid at 50 ◦C for 2 h. The reaction was cooled to room temperature and neutralised
with a solution of KHCO3 (0.25 M) and K2CO3 (0.5 M). FAMEs were collected by repeated
extraction of the reaction mixture with hexane [29] and resolved on a BPX-70 fused silica
capillary column (30m × 0.25mm × 25 µm) using an Agilent 6890 gas chromatograph,
(Agilent, Stockport, Cheshire, UK) equipped with flame ionisation detection [25]. Fatty
acids were identified by retention times relative to standards (37 FAMES, Sigma-Aldrich,
Poole, Dorset, UK). PBMC fatty acids are expressed as a proportion of total cell fatty acids.
2.5. Analysis of the T Cell Transcriptome by RNA Next-Generation Sequencing
Total RNA was isolated using mirVana RNA extraction kits (Invitrogen, Oxford,
Oxfordshire, UK) and then frozen at −80 ◦C, before being transported on dry ice for
RNAseq analysis. The purity of RNA was assessed using a 2100 Bioanalyser (Agilent). All
samples had RIN scores greater than 8.5. RNA was quantified using the Qubit RNA HS
Assay Kit (ThermoFisher Scientific).
RNA sequencing was carried out by Omega Bioservices (Norcross, GA, USA). Li-
braries were prepared using the TruSeq® Stranded mRNA Library Preparation kit (Illumina,
San Diego, CA, USA) and quantified using the Promega QuantiFluor dsDNA System on a
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Quantus Fluorometer (Promega, Madison, WI, USA). The size and purity of the libraries
were analysed using the High Sensitivity D1000 Screen Tape on an Agilent 2200 TapeStation
instrument. The libraries were normalised, pooled and clustered, and pair read sequencing
was performed for 150 cycles on an Illumina HiSeqX10 instrument (150 read cycles).
The quality control, normalisation and initial data analysis were carried out by Omega
Bioservices using the Illumina Basespace package (Version 2.0.1; www.illumina.com/produ
cts/by-type/informatics-products/basespace-sequence-hub/apps/rna-seq-alignment.htm
l). Sequencing reads were aligned to the Homo sapiens reference genome UCSC hg19 using
the STAR RNA sequence aligner [30]. Reference genes and transcripts were quantified
using the Salmon software package [31]. The Strelka variant caller was used to identifies
single nucleotide variants and small indels [32]. Gene counts, gene FPKMs, principal
component analysis and differential expression were produced using DESeq2 [33]. Tran-
scripts that differed between stimulated and unstimulated cells by at least 1.2-fold with
an adjusted p < 0.05 were considered to be differentially expressed. Pathway analysis
was carried out in house using the Ingenuity Pathway Analysis package. Pathways that
differed between unstimulated and stimulated cells by at least 1.2-fold with p < 0.05 and
enriched in ≥10 differentially expressed transcripts were considered to be significantly
altered. RNA sequencing data were validated by RT-qPCR using the SyberGreen method as
described [34] using the primers listed in Supplementary Table S1. Five genes were chosen
at random that differed significantly between unstimulated and stimulated T lymphocytes
at Baseline and represented the range of mitogen-induced changes detected by the arrays.
2.6. Statistical Analysis
Fatty acid composition data are presented as mean ± SEM, unless stated otherwise,
and analysed by two-way ANOVA with the type of oil as a fixed factor and time as a
repeated measure with Tukey’s post hoc correction using IBM SPSS Statistics for Windows
(Version 26.0, IBM, Armonk, NY, USA).
3. Results
3.1. Participant Characteristics
In total, 32 men and women were enrolled, of which 31 completed the study (Table 1).
One participant withdrew from the study because they could not tolerate the taste of
the FO [25] and was consequently excluded from all analyses. There were no significant
differences between groups in the characteristics of the participants.
3.2. Provision of Fatty Acids from Test Oils
The provision of saturated fatty acids (SFAs) per day by tCSO was similar to that from
FO (Table 2). FO provided 1.5-fold more 16:0 than tCSO, while tCSO provided 3-fold more
18:0 than FO. The amount of total monounsaturated fatty acids (MUFAs) provided by FO
was 1.5-fold greater (due primarily to greater amounts of 16:1n-7 and 18:1n-9) than that
provided by tCSO (Table 2). The total amount of n-6 PUFAs provided by tCSO was 13-fold
greater than that provided by FO due, mainly due to the 20-fold higher 18:2n-6 content of
the tCSO than FO (Table 2). The total amount of n-3 PUFAs provided by tCSO was 1.7-fold
greater than that provided by FO, due mainly to the higher 18:3n-3 (12-fold) and 22:5n-3
(5-fold) contents of the tCSO, while the 20:5n-3 and 22:6n-3 contents were similar between
the test oils (Table 2).
3.3. Effect of Dietary Supplementation on the Fatty Acid Composition of PBMCs
Dietary supplementation induced modest, statistically significant reductions in the
proportions of 18:1n-7 (tCSO −7.1%; FO −8%), 18:2n-6 (tCSO −9%; FO −3%) and 18:3n-6
(tCSO −20%; FO −40%) in PBMC total lipids (Table 3), although there was no significant
effect of the type of test oil. Dietary supplementation induced significant increases in the
proportions of 20:5n-3 (tCSO 13%; FO 13%) and 22:6n-3 (tCSO 5%; FO 16%) in PBMC total
lipids (Table 3). There was no significant effect of the type of test oil consumed on the
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proportions of 20:5n-3 and 22:6n-3. However, there was a significant time × test oil effect
on the proportion of 22:5n-3, such that there was a significant increase (29%) following
tCSO supplementation with 22:5n-3, but no detectable change after consuming FO (Table 3).
There was no significant effect of dietary supplementation or the type of test oil on the
proportion of any of the other fatty acids measured in PBMCs (Table 3). There were no
significant differences before or after dietary supplementation with either test oil on the
fatty acid composition of PBMCs between the subgroups, from which T cells were analysed
by RNAseq and the corresponding whole groups (Supplementary Table S2).
Table 3. The effect of dietary supplementation with tCSO or FO in the fatty acid composition of PBMCs. Values are
mean ± SEM. Data were analysed by ANOVA with time as a repeated measure and the type of oil as a fixed factor for all
(n = 31) participants. df were 1.60. There were no single factor effects of the type of test oil. The fatty acid composition and
statistical analyses of PBMCs from the subgroup of participants whose samples were used in RNAseq analyses are shown
in Supplementary Table S2.
Proportion of Total Fatty Acids ANOVA
% Time Time × Test Oil
FO tCSO F p F p
Start End Start End
14:0 0.5 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 0.82 0.35 0.25 0.88
16:0 19.8 ± 0.9 19.9 ± 1.2 21.3 ± 1.2 18.6 ± 1.2 3.34 0.08 4.14 0.05
16:1n-7 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.04 0.85 0.42 0.52
18:0 27.7 ± 0.7 27.4 ± 0.5 27.6 ± 0.7 27.0 ± 0.8 0.83 0.37 1.21 0.73
18:1n-9 14.8 ± 0.5 15.1 ± 0.4 13.8 ± 0.5 15.3 ± 0.5 5.98 0.02 2.47 0.12
18:1n-7 1.4 ± 0.1 1.3 ± 0.0 1.3 ± 0.0 1.2 ± 0.1 6.22 0.02 0.01 0.91
18:2n-6 6.7 ± 0.3 6.1 ± 0.2 6.2 ± 0.2 6.0 ± 0.2 5.35 0.02 1.36 0.24
18:3n-6 0.5 ± 0.0 0.4 ± 0.0 0.5 ± 0.1 0.3 ± 0.0 3.895 0.04 0.42 0.52
18:3n-3 1.0 ± 0.1 1.0 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 0.45 0.51 0.70 0.79
20:0 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.79 0.39 1.22 0.27
20:1n-9 1.2 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 1.65 0.20 1.35 0.25
20:2n-6 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.001 0.98 0.55 0.46
20:3n-6 1.8 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 1.1 0.31 4.88 0.07
20:4n-6 16.5 ± 0.9 16.6 ± 0.9 16.3 ± 1.1 18.4 ± 1.1 2.49 0.12 2.42 0.13
20:5n-3 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 4.51 0.04 0.07 0.80
22:5n-3 1.9 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 2.2 ± 0.1 12.22 0.001 5.35 0.02
22:6n-3 2.1 ± 0.1 2.2 ± 0.1 1.9 ± 0.1 2.2 ± 0.1 4.20 0.04 1.13 0.30
3.4. The Effect of Dietary Supplementation on the Number of Differentially Expressed Transcripts
in Activated Compared to Unstimulated CD3+ T Cells
The findings of the RNAseq analysis were validated by RT-qPCR. The five genes
tested showed a significant difference between stimulated and unstimulated cells in the
same direction by both techniques (Supplementary Figure S1).
Mitogen stimulation of T cells collected at Baseline induced differential expression
of 4310 transcripts, of which 2517 (59.4%) were up-regulated compared to unstimulated
cells (Figure 1A,B). Mitogen stimulation after FO supplementation induced differential
expression compared to unstimulated cells of 4769 transcripts, of which 2723 (57.1%) were
up-regulated (Figure 1A,B). Mitogen stimulation after tCSO supplementation induced
differential expression compared to unstimulated cells of 4652 transcripts, among which
2514 (54.0%) were up-regulated (Figure 1A,B). In total, 2758 transcripts were expressed
differentially at Baseline and after supplementation with either test oil, of which 65.8%
were up-regulated.
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did not v rlap with tra scripts that were differentially expressed after supplementation
with either test oil (Figure 1A). Mitogen stimulation aft r FO upplementation induced
up-regulation of 477 (17.5%) transcripts that did not ov rlap with thos up-regulated at
Baseline or after tCSO suppleme tation. Mitogen stimulation after tCSO s pl men ation
induced up-r gulation of 320 (12.7%) transcripts that did not overlap with those up-
reg lated at Baseline or after FO supplementa ion (Figure 1A). Overall, 2,014 transcripts
that were up-regulated at Baseline wer also up-re lated after FO supplementation, while
1,989 transcripts th were up-regul ted at Baseline were also up-regulated after tCSO
supplementation. Furth , 2,021 transcripts wer up-regulated by supplement tion with
both test oils, of which 1,986 (98.2%) were also up-regulated at Baseline (Figure 1A).
Mitogen stimulation at Baseline induced down-regulation of 396 (22.1%) transcripts
that did not overlap with transcripts that were down-regulated after supplementation
with either test oil (Figure 1B). Mitogen stimulation after FO supplementation induced
down-regulation of 616 (30.1%) transcripts that were not down-regulated at Baseline or
after tCSO supplementation. Mitogen stimulation after tCSO supplementation induced
down-regulation of 631 (29.5%) transcripts that were not down-regulated at Baseline or
after FO supplementation (Figure 1B). In total, 1,241 (61%) transcripts that were down-
regulated after FO supplementation were also down-regulated by supplementation with
tCSO (Figure 1B).
In this study, 45 (1.8%) of the transcripts up-regulated in mitogen-stimulated compared
to mitogen-unstimulated T cells at Baseline were down-regulated after supplementation
with FO. Additionally, 25 (1%) of the transcripts up-regulated in mitogen-stimulated com-
pared to unstimulated T cells at Baseline were down-regulated after supplementation tCSO
(Figure 2A). Furthermore, 34 (1.8%) transcripts that were down-regulated at Baseline were
up-regulated after FO supplementation; 22 (1.2%) transcripts that were down-regulated
at Baseline were down-regulated after tCSO supplementation. Six transcripts that were
up-regulated by mitogen stimulation at Baseline were down-regulated after supplementa-
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tion with either FO or tCSO, namely INSM2, C1orf105, DKFZp779M0652, CLDN5, PPIAL4F
and THRB (Figure 2A). Three transcripts that were down-regulated at Baseline were up-
regulated after supplementation with either FO or tCSO, namely GOLGA8S, TRIM39-RPP21
and EPHX3 (Figure 2B).
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3.5. The Effect of Dietary Supplementation on the Most Differentially Expressed Transcripts in
Activated Compared to Unstimulated CD3+ T Cells
Four transcripts were among the 20 most up-regulated transcripts at Baseline and
after supplementation with either FO or tCSO, namely interleukin (IL)-17F, IL-5, Kinesin
Family Member 1A (KIF1A) and Thymidylate Synthetase (TYMS) (Table 4). In addition,
Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) and Cystathionine β-
Synthase-like protein (CBSL) were among the 20 most differentially up-regulated transcripts
after supplementation with FO or tCSO, but not in cells collected at Baseline (Table 4).
Gap junction protein-Beta-2 (GJB2) and Minichromosome Maintenance 10 Replication
Initiation Factor (MCM10) were among the most up-regulated transcripts at Baseline
and after supplementation with tCSO, but not with FO (Table 4). Zinc-Finger BED-Type
Containing-2 (ZBED2), IL-22 and spindle pole body component 25 (SPC25) were among
the 20 most up-regulated transcripts at Baseline and after supplementation with FO, but
not with tCSO (Table 4).
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Table 4. The 20 most changed transcripts in response to stimulation with Concanavalin A in T cells collected from women
either before supplementation or after supplementation with either tCSO or FO. Values are log2 fold difference between
mitogen-stimulated and -unstimulated cells.
Difference in mRNA Expression in Concanavalin A-Stimulated Cells and Unstimulated Cells
Baseline Post tCSO Supplementation Post FO Supplementation
n 16 8 8
Gene log2 FoldChange Adjusted p Gene
log2 Fold




CXCL9 8.97 1.16 × 10−32 KIF20A 8.71 6.13 × 10−73 CSF2 8.50 2.48 × 10−26
IL17A 8.40 1.14 × 10−15 IL17F 8.68 9.23 × 10−21 GJB2 8.13 1.15 × 10−12
IL17F 7.84 6.67 × 10−21 ZBED2 8.60 5.08 × 10−45 CAVIN3 8.03 1.17 × 10−17
GJB2 7.80 6.24 × 10−26 SPC25 8.60 3.61 × 10−34 RIBC2 7.91 1.46 × 10−17
CCL17 7.69 5.03 × 10−18 IL22 8.57 3.52 × 10−17 IL17F 7.91 2.68 × 10−17
ZBED2 7.63 3.78 × 10−28 IL17A 8.50 2.94 × 10−12 CBSL 7.84 2.09 × 10−11
CXCL10 7.42 1.20 × 10−18 XIRP1 8.40 6.14 × 10−26 MCM10 7.76 2.56 × 10−29
IL5 7.27 1.62 × 10−15 PKMYT1 8.32 2.78 × 10−68 IL5 7.57 2.19 × 10−07
HIST1H2BH 7.20 4.41 × 10−29 IL5 8.23 5.14 × 10−13 CCL1 7.53 6.48 × 10−16
IFNG 7.19 3.46 × 10−27 UHRF1 8.17 1.65 × 10−140 CDC25C 7.49 3.57 × 10−17
EBI3 7.17 1.53 × 10−46 KIF18B 8.13 5.09 × 10−88 TYMS 7.47 3.65 × 10−20
IL22 7.15 1.04 × 10−15 CCNB2 8.11 5.83 × 10−67 CDC25A 7.40 1.26 × 10−20
SPC25 7.14 1.82 × 10−19 KIF1A 8.08 8.82 × 10−22 CDC20 7.33 3.20 × 10−17
FLJ21408 7.13 2.02 × 10−20 RRM2 8.02 2.36 × 10−49 KIF1A 7.33 1.63 × 10−16
KIF1A 7.06 8.69 × 10−23 TYMS 8.02 4.02 × 10−78 FGF2 7.29 9.95 × 10−16
IL21 7.02 4.12 × 10−21 BIRC5 7.85 5.30 × 10−73 IL24 7.29 1.20 × 10−11
MCM10 7.01 7.03 × 10−23 CBSL 7.82 1.59 × 10−15 BIRC5 7.28 5.84 × 10−16
MYBL2 7.01 1.29 × 10−28 LINC01132 7.80 4.72 × 10−23 ANXA3 7.24 3.10 × 10−09
TYMS 6.97 1.64 × 10−25 GNG4 7.76 2.32 × 10−33 PBK 7.24 2.41 × 10−16
DLGAP5 6.96 7.44 × 10−25 STC2 7.69 6.13 × 10−20 SMIM11A 7.19 0.012
Down-regulated genes
TREM2 −6.45 3.34 × 10−13 RNASE1 −8.15 5.49 × 10−23 SMN1 −26.27 5.38 × 10−17
FAM198B −6.01 2.85 × 10−10 TREM2 −6.77 1.31 × 10−12 EEF1E1_BLOC1S5 −23.38 1.23 × 10−13
GPNMB −5.90 2.93 × 10−21 HSFX2 −6.76 0.04 LOC102723996 −23.19 2.00 × 10−13
RNASE1 −5.84 2.34 × 10−07 CNTNAP2 −6.53 4.28 × 10−10 RNASE1 −7.60 8.65 × 10−05
APOC2 −5.67 3.95 × 10−07 OLR1 −6.27 5.65 × 10−07 TREM2 −6.96 2.91 × 10−07
KCNJ5 −5.63 1.03 × 10−07 LINC00891 −6.26 0.002 GPNMB −6.17 8.35 × 10−15
A2M −5.58 9.60 × 10−17 F13A1 −6.24 1.54 × 10−11 LILRB5 −5.99 6.70 × 10−06
RAB42 −5.42 4.82 × 10−08 GPNMB −6.15 5.01 × 10−28 CD163 −5.98 1.05 × 10−12
LILRB5 −5.23 2.02 × 10−07 C1QA −6.09 2.01 × 10−07 CNTNAP2 −5.91 4.45 × 10−09
FCN1 −5.10 2.49 × 10−10 FPR3 −6.06 6.52 × 10−16 SLCO2B1 −5.88 2.22 × 10−08
DCANP1 −5.08 1.11 × 10−08 FAM198B −6.00 1.72 × 10−10 FAM198B −5.83 0.0003
STAB1 −5.01 1.04 × 10−13 GTF2IP4 −5.85 0.02 DCANP1 −5.69 1.10 × 10−05
ATP6V0D2 −4.98 6.54 × 10−07 STAB1 −5.80 4.66 × 10−21 MSR1 −5.66 0.0001
CNTNAP2 −4.91 2.72 × 10−15 HNMT −5.76 4.85 × 10−08 CLEC10A −5.62 6.39 × 10−10
CLEC9A −4.84 5.86 × 10−07 A2M −5.74 5.33 × 10−15 F13A1 −5.57 1.77 × 10−05
F13A1 −4.79 2.04 × 10−09 CLEC10A −5.66 5.39 × 10−10 DNASE1L3 −5.55 1.88 × 10−06
APOE −4.72 1.20 × 10−16 DCANP1 −5.56 4.06 × 10−06 THBD −5.53 0.001
HS3ST2 −4.72 0.0002 LILRB5 −5.37 1.51 × 10−07 FABP4 −5.42 0.002
CD1D −4.54 2.05 × 10−05 PDK4 −5.28 7.81 × 10−11 LOC387810 −5.41 0.0001
NLRC4 −4.44 1.59 × 10−05 CLEC7A −5.24 5.99 × 10−12 UMODL1-AS1 −5.32 3.56 × 10−05
3.6. Effect of Dietary Supplementation on Differentially Expressed Pathways in Activated CD3+
T Cells
The number of significantly enriched pathways in mitogen-stimulated compared to
unstimulated cells (≥10 differentially expressed transcripts; ≥1.2-fold difference from
unstimulated cells, α < 0.05) was greater following tCSO supplementation (617 pathways)
than after FO supplementation (601 pathways) or at Baseline (517 pathways).
The 25 most altered pathways were either associated with immune cell function or
cell proliferation (Table 5, Figure 3). Of these, 14 pathways were differentially expressed
in stimulated compared to unstimulated cells at Baseline and after supplementation with
either test oil (Table 5), and 3 pathways were differentially expressed at Baseline and
after FO supplementation, while 3 different pathways were differentially expressed at
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Baseline and after tCSO supplementation. Additionally, three pathways were differentially
expressed at Baseline alone, three others were differentially expressed only after FO sup-
plementation and five pathways were differentially expressed after tCSO, but not after FO
supplementation or at Baseline (Table 5).




Figure 3. The proportions of up-regulated transcripts in the 20 most altered pathways at Baseline. Values are proportions 
(%) of up-regulated transcripts in stimulated compared to unstimulated cells at Baseline and after supplementation with 
either FO or tCSO in the 20 most altered pathways at Baseline grouped according to their putative roles (A) immune 
response and (B) cell proliferation. The names of some pathways have been shortened. The full pathway names are shown 
in Table 5. 
  
Figure 3. The proportions of up-regulated transcripts in the 20 most altered pathways at Baseline. Values are proportions (%)
of up-regulated transcripts in stimulated compared to unstimulated cells at Baseline and after supplementation with either
FO or tCSO in the 20 most altered pathways at Baseline grouped according to their putative roles (A) immun response and
(B) cell pr lifer tion. Th names of some pathway have b en s ortened. The full pathway names are sho n i Table 5.
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Table 5. The effect of dietary supplementation with the test oils on mitogen-induced changes in the expression of the top
25 most altered pathways.
Pathway −log(p) Ratio No Overlap with Dataset(Number, %)
Baseline
Kinetochore Metaphase Signalling Pathway 14.4 0.43 51/101 (50%)
Hepatic Fibrosis/Hepatic Stellate Cell Activation 11.5 0.31 115/186 (62%)
Cardiac Hypertrophy Signalling (Enhanced) 11.1 0.22 343/497 (69%)
Th1 and Th2 Activation Pathway 11 0.31 103/171 (60%)
STAT3 Pathway 10.6 0.33 82/135 (61%)
HMGB1 Signalling 10.0 0.30 105/165 (64%)
IL-10 Signalling 9.6 0.41 37/70 (53%)
Role of BRCA1 in DNA Damage Response 9.4 0.39 46/80 (57%)
Hepatic Cholestasis 8.5 0.27 122/186 (66%)
IL-17 Signalling 8.4 0.27 123/187 (66%)
Airway Pathology in Chronic Obstructive Pulmonary Disease 8.0 0.31 66/118 (56%)
GADD45 Signalling 8.0 0.68 5/19 (26%)
Molecular Mechanisms of Cancer 7.9 0.22 280/400 (70%)
Breast Cancer Regulation by Stathmin1 7.8 0.20 431/590 (73%)
Cell Cycle Control of Chromosomal Replication 7.7 0.41 30/56 (54%)
Aryl Hydrocarbon Receptor Signalling 7.6 0.29 88/143 (62%)
Tumor Microenvironment Pathway 7.5 0.27 113/176 (64%)
Hereditary Breast Cancer Signalling 7.4 0.29 93/140 (66%)
Role of Cytokines in Mediating Communication between Immune
Cells 7.3 0.41 27/54 (50%)
Erythropoietin Signalling Pathway 7.3 0.27 114/173 (66%)
Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritis 7.2 0.22 220/314 (70%)
PI3K/AKT Signalling 6.9 0.26 129/184 (70%)
Th2 Pathway 6.7 0.28 87/136 (64%)
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 6.7 0.41 26/49 (53%)
Oestrogen-Mediated S-phase Entry 6.7 0.54 11/26 (42%)
Post-FO supplementation
Kinetochore Metaphase Signalling Pathway 14.6 0.42 6/101 (6%)
STAT3 Pathway 12.1 0.34 15/135 (11%)
Th1 and Th2 Activation Pathway 10.3 0.29 21/171 (12%)
IL-10 Signalling 10.2 0.41 9/70 (13%)
Cardiac Hypertrophy Signalling (Enhanced) 9.8 0.21 103/497 (21%)
Hepatic Fibrosis/Hepatic Stellate Cell Activation 9.4 0.27 60/186 (32%)
Role of Pattern Recognition Receptors in Recognition of Bacteria
and Viruses 9.3 0.29 35/154 (23%)
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Table 5. Cont.
Pathway −log(p) Ratio No Overlap with Dataset(Number, %)
HMGB1 Signalling 9.3 0.29 27/165 (16%)
Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 9.2 0.36 19/90 (21%)
IL-17 Signalling 8.8 0.27 60/187 (32%)
Airway Pathology in Chronic Obstructive Pulmonary Disease 8.7 0.31 46/118 (39%)
Hepatic Cholestasis 8.4 0.26 50/186 (27%)
Cell Cycle Control of Chromosomal Replication 8.2 0.41 0/56 (0%)
Oestrogen-Mediated S-phase Entry 8.0 0.58 0/26 (0%)
Role of BRCA1 in DNA Damage Response 7.9 0.35 2/80 (3%)
Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritis 7.9 0.22 62/314 (20%)
Aryl Hydrocarbon Receptor Signalling 7.8 0.28 26/143 (18%)
Erythropoietin Signalling Pathway 7.6 0.26 28/173 (16%)
Diff. Reg. of Cytokine Production in Macrophages and T Helper
Cells by IL-17A and IL-17F 7.5 0.67 1/18 (6%)
Molecular Mechanisms of Cancer 7.4 0.20 45/400 (11%)
Crosstalk between Dendritic Cells and Natural Killer Cells 7.4 0.33 11/89 (12%)
TREM1 Signalling 7.3 0.35 13/75 (17%)
GADD45 Signalling 7.1 0.63 0/19 (0%)
Role of Cytokines in Mediating Communication between Immune
Cells 7.0 0.39 25/54 (46%)
Protein Ubiquitination Pathway 6.9 0.22 27/273 (10%)
Post tCSO supplementation
Kinetochore Metaphase Signalling Pathway 14.4 0.43 6/101 (6%)
IL-10 Signalling 11.1 0.44 9/70 (13%)
Th1 and Th2 Activation Pathway 11 0.31 19/171 (11%)
Hepatic Fibrosis/Hepatic Stellate Cell Activation 10.5 0.30 50/186 (27%)
Airway Pathology in Chronic Obstructive Pulmonary Disease 10.4 0.35 42/118 (36%)
Hepatic Cholestasis 9.9 0.29 46/186 (25%)
Diff. Reg. of Cytokine Production in Macrophages and T Helper
Cells by IL-17A and IL-17F 9.8 0.78 1/18 (6%)
Role of Pattern Recognition Receptors in Recognition of Bacteria
and Viruses 9.6 0.31 31/154 (20%)
STAT3 Pathway 9.4 0.32 11/135 (8%)
IL-17 Signalling 8.9 0.28 55/187 (29%)
Differential Regulation of Cytokine Production in Intestinal
Epithelial Cells by IL-17A and IL-17F 8.7 0.65 4/23 (17%)
Granulocyte Adhesion and Diapedesis 8.2 0.28 67/173 (39%)
Role of Cytokines in Mediating Communication between Immune
Cells 8.0 0.43 22/54 (41%)
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Table 5. Cont.
Pathway −log(p) Ratio No Overlap with Dataset(Number, %)
Role of BRCA1 in DNA Damage Response 8.0 0.36 1/80 (1%)
HMGB1 Signalling 8.0 0.28 24/165 (15%)
Altered T Cell and B Cell Signalling in Rheumatoid Arthritis 7.9 0.34 20/90 (22%)
Airway Inflammation in Asthma 7.9 0.53 3/32 (9%)
Cardiac Hypertrophy Signalling (Enhanced) 7.8 0.20 92/497 (19%)
Systemic Lupus Erythematosus in B Cell Signalling Pathway 7.8 0.24 43/275 (16%)
Th2 Pathway 7.7 0.29 15/136 (11%)
Aryl Hydrocarbon Receptor Signalling 7.6 0.29 23/143 (16%)
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 7.5 0.43 0/49 (0%)
PI3K/AKT Signalling 7.3 0.26 12/184 (7%)
Erythropoietin Signalling Pathway 7.3 0.27 23/173 (13%)
Role of Hypercytokinemia/Hyperchemokinemia in the
Pathogenesis of Influenza 7.2 0.34 27/86 (31%)
Dietary supplementation with either FO or tCSO increased the proportions of up-
regulated transcripts in 18/25 of the most altered pathways identified at Baseline (Figure 3).
The proportion of up-regulated transcripts in the ‘Role of cytokines in mediating communi-
cation between immune cells’ pathway was similar irrespective of dietary supplementation
(Figure 3A). The proportion of up-regulated transcripts in breast cancer regulation by
the stathmin-1 pathway was similar at Baseline to after supplementation with tCSO, but
approximately 3-fold greater after FO supplementation (Figure 3B).
4. Discussion
The findings show that incorporation of 20:5n-3 and 22:6n-3 into PBMC total lipids
from tCSO was similar to that from FO when these fatty acids are consumed according to
the daily recommendation made by the UK Government to maintain general health [22].
Despite equivalence in the incorporation of 20:5n-3 and 22:6n-3 into PBMCs, there were
differences between test oils in the mitogen-induced changes to the expression of the CD3+
T cell transcriptome.
We have shown that dietary supplementation with either tCSO or FO induced compa-
rable increments of 20:5n-3 and 22:6n-3 concentrations in individual plasma lipid classes in
samples from the present study [25]. Since leukocytes can assimilate fatty acids from both
lipoprotein [35] and non-esterified fatty acid pools [36], these findings show an overall
enrichment of 20:5n-3 and 22:6n-3 in the lipid environment to which T cells were exposed
in vivo. Consequently, 20:5n-3 and 22:6n-3 were also enriched in PBMC lipids, independent
of the type of oil supplement. The proportions of 22:5n-3, 16:1n-7, 18:2n-6, 18:3n-6 and
20:2n-6 were also increased in quiescent PBMCs after supplementation with the test oils,
although they were not increased in plasma lipids [25]. Leukocytes can preferentially
accumulate PUFAs from their environment [37]; however, the composition of leukocyte
cell membranes reflects primarily the specificity of phospholipid biosynthesis [38]. The
proportions of 22:5n-3, 16:1n-7, 18:2n-6, 18:3n-6 and 20:2n-6 increase in activated leuko-
cytes, particularly T cells [39–41], as a result of changes in the specificity of phospholipid
biosynthesis including increased phospholipid acyl-remodelling processes [37,38]. One
possible explanation for enrichment of 22:5n-3, 16:1n-7, 18:2n-6, 18:3n-6 and 20:2n-6 in
PBMCs in the present study is that it reflects induction of membrane changes by partial
activation of the cells due by cell processing in vitro.
There is considerable evidence that consumption of oils containing 20:5n-3 and 22:6n-3
can suppress the immune response [20] and modify the mRNA expression of individual
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genes that are involved in immune cell function [42–44]. However, there is limited informa-
tion about the effect of dietary supplementation with oils containing 20:5n-3 and 22:6n-3 on
activation-associated changes in the T cell transcriptome. Previous analyses of the effect of
dietary supplementation with FO or seed oils showed differential changes in the expression
of the transcriptome of PBMCs. FO supplementation has been shown to increase the mRNA
expression of genes involved in cell cycling in quiescent PBMCs compared to a sunflower
oil supplement [45]. Others have shown that consumption of 1.8 g/day of 20:5n-3 plus
22:6n-3 for 26 weeks in elderly men and women induced the differential expression of
1,040 genes in quiescent PBMCs, primarily down-regulation of transcripts involved in
inflammatory and atherogenic pathways, compared to 298 differentially expressed genes
following supplementation with 4 g/day of sunflower oil [46]. Moreover, Polus et al. found
the differential expression of genes involved in inflammation and lipid metabolism in
whole blood from obese women after supplementation with 1.8 g/day of 20:5n-3 plus
22:6n-3 compared to an undisclosed placebo [47]. None of these studies investigated the
effect of dietary supplementation on changes induced in the leukocyte transcriptomes by
mitogen stimulation. Therefore, it is uncertain whether the differences in gene expression
in quiescent PBMCs are reflected in activated cells or if they related to leukocyte function.
Furthermore, because these studies investigated the transcriptome of PBMCs, instead of
single cell types, the findings are at risk of confounding due to variation in the relative
proportions of each cell type both between individuals and within the same participant
over time. None of the previous studies disclosed whether the data were corrected for the
proportions of different types of leukocytes.
The present study showed differential effects between the test oils and compared
to Baseline on mitogen-induced changes in individual genes and pathways in CD3+ T
lymphocytes. These findings suggested that consuming these test oils altered the capacity
of T cells to undergo changes in transcription that are associated with the immune response.
Only 20% of the most up-regulated and 35% of the most down-regulated transcripts
were among the most differentially expressed at Baseline and after supplementation with
either test oil. This suggests that, despite comparable changes in PBMC lipid composition,
these test oils differed in their effects on the expression of the transcriptome. Moreover,
the direction of mitogen-induced change in expression was reversed for a proportion
(<2%) of differentially expressed genes irrespective of the test oil supplement. Two of the
most down-regulated transcripts were considered anomalies, namely CD163, which is a
macrophage-specific scavenger receptor [48], and CD1d, a marker expressed by antigen-
presenting cells including CD19+ CD1d+ regulatory B lymphocytes [49] that is also a target
for invariant natural killer T cells [50]. One possible explanation is that there was low-level
contamination of the T cell preparations with macrophages or CD1d+ B cells that was not
detected by routine assessment of the purity of the T cell preparation by flow cytometry. If
so, the decrease in the expression of these markers could be explained by reduction in the
proportion of contaminating cell populations by the mitogen-induced expansion of CD3+
T lymphocytes.
The most altered pathways were associated with cell proliferation and immune re-
sponse in stimulated compared to unstimulated cells. A previous RNAseq analysis of
PBMC cultures stimulated with anti-CD3 antibodies also showed increased expression
of pathways involved in immune function and cell division [51], although differences
between this previous report and the present findings may be due to analysis of a mixture
of cell types in the previous study. Both FO and tCSO increased the number of up-regulated
transcripts in pathways involved in cell division [52] and immune-regulatory pathways
such as interleukin-17 and interleukin-10 signalling [20,53]. This suggests that even modest
20:5n-3 and 22:6n-3 intakes might modify immune function, possibly by changing the
balance between cross-talking pathways [54].
Inevitably, there are some limitations to the study design. These include the mod-
est number of participants, although groups were well-matched, which was based on a
previous investigation of the effect of FO supplementation on the fatty acid composition
Nutrients 2021, 13, 3116 15 of 18
of PBMCs [7], as there are no previous studies of the effect of supplementation with FO
on measurements of the expression of the T cell transcriptome by RNAseq on which to
base a statistical power calculation. For this reason, the current findings could be regarded
as exploratory. It is possible that there may have been low-level contamination of the T
lymphocyte preparations that was not detected by the limited assessment of the cell com-
position. There were no analyses of cell function, such as cytokine secretion, because these
measurements were not required to address the primary aim of the study. Nevertheless,
previous studies have shown that omega-3 PUFA-induced changes in cytokine mRNA
levels, including IL-17A and IL-5 in human [55] and murine [56] T cells or PBMCs, are
related directly to their concentration in cell culture supernatants. Therefore, although
the present study did not investigate whether changes in cytokine mRNA levels were
associated with differences in their respective concentrations, it is probable that differences
in gene expression would have altered cytokine secretion.
These analyses do not permit deduction of the underlying mechanism by which
such differential effects between test oils were induced. Although different individuals
were randomised to either test oil, these groups were composed of women who were
well matched with similar compliance, and so any effect of confounding due to different
participants in each arm of the trial is likely to be modest. The quantities of the test oils that
were consumed were designed to deliver similar amounts of 20:5n-3 plus 22:6n-3, but they
were not matched for the other fatty acids present. For example, the amounts of n-6 PUFAs,
primarily 18:2n-6, were approximately 10-fold greater in tCSO than in FO. These differences
in the fatty acid composition of the test oils were not reflected in the composition of PBMC
total lipids. This suggest that any influence of difference in the amounts of fatty acids
provided between test oils on cell function is unlikely to be mediated via changes in the
composition of T cell membranes alone. PPARγ activity in PBMCs has been shown to be
modified by dietary supplementation with FO [43,57]. Therefore, one possible explanation
for the differential effects of the test oil on the expression of the T cell transcriptome is via
the actions of ligand-activated fatty acid-binding transcription factors, such as members
of the PPAR family. Furthermore, dietary supplementation with FO or olive oil has been
shown to induce changes in DNA methylation of PBMCs that are contingent on the type
of oil [58], and the treatment of Jurkat T lymphocyte leukaemia cells with physiologically
relevant amounts of 22:6n-3 or 18:1n-9 induced differential methylation of individual CpG
loci [59]. This suggests that induction of altered epigenetic regulation may be one additional
or alternative mechanism to any direct effect on PPAR activity by which supplementation
with FO or tCSO could modify mitogen-induced changes in the T cell transcriptome.
5. Conclusions
The findings of the present study show for the first time that consuming an amount
of FO or tCSO oil, which each provided 450 mg/day of 20:5n-3 plus 22:6n-3, the amount
recommended by the UK Government for maintaining general health [22], modified the
activation-induced changes in the expression of the T cell transcriptome, and thus may
alter the regulation of their function. These changes to the response of the transcriptome to
activation differed between test oils, which implies that 20:5n-3 and 22:6n-6 were not the
only mediators of altered transcription. One possible implication of these findings is that
consuming the amount of 20:5n-3 plus 22:6n-3 recommended by the UK Government [22]
can induce changes in the T cell transcriptome that are relevant for understanding dif-
ferences between individuals in their response to infection or vaccination. Moreover, the
precise effect on the transcriptome of supplements containing EPA plus DHA may be
contingent on the overall fatty acid composition of the oil.
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composition of PBMCs from the participants subgroups from which T cells were used in RNAseq
analysis.
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